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Introduction: The polymer PEI-MP (polyethyleneiminomethyl phosphonic acid) that might be 
labeled with 99mTc and 188Re, have a strong potential for diagnosis and metabolic radiotherapy, 
respectively. The aim of this study was to evaluate the efficacy of 99mTc-PEI-MP for diagnosis and 
188Re-PEI-MP as therapeutic agent, in a comparative study using in vitro and in vivo models of 
bladder cancer and osteossarcoma. 
Material and Methods: In vitro studies were performed using the cell lines of bladder cancer 
(CRL-1472) and of osteossarcoma (MNNG-HOS). Cytotoxicity of PEI-MP was investigated using 
 
  
  
  
 
 
 
 
 
the MTT test and flow cytometry. Radiochemical purity of 188Re-PEI-MP and 99mTc-PEI-MP was 
achieved using ascending microchromatography. Celular uptake studies were performed using 
the complexes 188Re-PEI-MP, 99mTc-PEI-MP, Na188ReO4 and Na99mTcO4. Cell samples were 
collected during four hours, centrifuged to separate supernatant and pellet. Subsequently, the 
radioactivity of each portion was counted to determine percentage of uptake. The in vivo studies 
were performed using twelve groups of Balb/c nu/nu mice: four normal groups injected with 
Na188ReO4, 188Re-PEI-MP, Na99mTcO4 and 99mTc-PEI-MP, four with bladder carcinoma 
xenotransplants and four with osteosarcoma xenotransplants injected with the same complexes. 
After injection of the radiopharmaceuticals, were acquired dynamic and static images for 2 and 4 
hours. For biodistribution proposes, mice were euthanized 2 and 4 hours after injection and organ 
samples where weighted and counted in a well-counter to obtain percentage injected activity per 
gram of organ (%ID/g).  
Results: The MTT assay and flow cytometry tests showed that PEI-MP is not cytotoxic. The 
radiochemical purity of 188Re-PEI-MP and 99mTc-PEI-MP was ≥85%. The uptake studies 
demonstrated that the uptake was higher for 188Re-PEI-MP and 99mTc-PEI-MP in relation to their 
controls, and higher for 188Re-PEI-MP e relation to 99mTc-PEI-MP. Biodistribution results, with 
Na188ReO4 and Na99mTcO4, showed a higher uptake by the thyroid, bladder and stomach, 
following a normal biodistribution. The biodistribution with 188Re-PEI-MP and 99mTc-PEI-MP 
showed that the excretion of these complexes occurs primarily through the renal system, with a 
small fraction being eliminated by the hepatobiliary system. Tumor/muscle ratio for 188Re-PEI-MP 
was >1 for the xenotransplants of osteosarcoma and >1.5 to xenotransplants of bladder cancer. 
Conclusions: Considering the results, 188Re-PEI-MP seems to be promising in the treatment of 
both types of cancer, but with a greater potential for bladder cancer. 99mTc-PEI-MP seems to be 
optimal for diagnosis of both types of cancer. 
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